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ABSTRACT 
Ciprofloxacin (CF) is one of the topmost selling antibiotics and it is available at a cheap cost which is used to treat many bacterial infections. Many 
research scientists are working on this drug for various applications on different drug delivery systems. The main objective of this paper is to 
enlighten about the details of pure drug CF and its delivery systems along with current research on this drug. This review focused on history, 
pharmacokinetics, mechanism of action, types of dosage form available in the market with their cost, current research going on this drug with their 
applications and methods development for estimation of CF. It also highlighted the possible interactions and adverse drug reactions of CF and 
patents available. The present review revealed that the only analytical method for estimation of CF was developed in the first decade, few drug 
delivery systems (DDS) of CF were developed in the second decade and more research work on the development of novel DDS of CF founded in the 
last decade. 
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Ciprofloxacin (CF) is an antibiotic which is available at a cheap cost 
[1] and used to treat many bacterial infections [2]. It belongs to 
fluoroquinolones category and is a broad spectrum second 
generation antibacterial agent [3]. It is mostly used to treat gram 
negative bacterial infections, urinary tract infections, skin, 
ophthalmic, respiratory, bone and joint, intraabdominal infections 
bacterial diarrheal infections [4] and periodontal pathogens [5]. But 
it is not effective against viral diseases. It is a nucleic acid synthesis 
inhibitor [6].  
It is one of the topmost selling antibiotics [1] and numbers of 
researchers are working with this drug for different applications or 
improvements in its applications.  
Hence, the search criteria used in the present review were the 
research work on the development of novel drug delivery systems of 
CF in the last 3 decades (1985-2017) including the patents and 
different marketed products of CF with their price along with the 
properties and uses of CF. Properties [7] of CF are shown in table 1 
and the storage temperatures required for different dosage forms is 
between 5-25 °C [8]. 
 
Table 1: Properties of ciprofloxacin 
Name of property Description Reference number 
State Solid  
7 Water solubility 1.35 mg/ml 
Melting point ( °C) 255-257 
Log P -0.57 
pKa (Strongly Acidic) 5.76 
pKa (Strongest Basic) 8.68 
Biological half-life 3.5 h 
 
History 
Quinolones were first developed in 1960's, then they were classified into 
generations based on antimicrobial activity. In the first generation, 
nalidixic acid was developed in 1962 to treat urinary tract infections and 
later in 1980 by insertion of F atom in quinolone ring a 2nd generation 
CF was developed to treat a number of infections [9].  
Pharmacokinetic parameters 
The pharmacokinetic parameters of CF are listed in table 2 
Absorption 
60-80% CF is rapidly absorbed with tmax of 1 to 1.5 h, when given by 
oral route and it has no significant effect when administered with food, 
but altered with ingestion of sucralfate, Fe2SO4 and antacids [7]. 
Distribution 
It penetrates well into the most of the body fluids and tissues. Tissue 
concentrations often exceed serum concentrations in both men and 
women, particularly in genital tissue, including the prostate [3].  
Metabolism 
It is metabolized into oxoCF, sulfoCF and other active metabolites. 
On oral administration, approximately 15% of the dose is converted 
into four metabolites identified in human urine which are less active 
than unchanged CF [8]. 
Elimination 
50% of CF are eliminated by kidney, 15% by feces, and 45% of liver 
and other intestinal mucosal secretions [3]. 
USES/Indication 
CF is used to treat acute sinusitis, lower respiratory tract infection, 
chronic bronchitis, hospital acquired pneumonia, kidney, urinary tract, 
diarrheal and abdominal infections, skin and soft tissue, bone and joint 
infections, acute otitis and uncomplicated cystitis and gonorrhea. 
Mechanism of action 
The fluoroquinolones act by inhibiting type 2 bacterial DNA 
topoisomerases, DNA gyrase and topoisomerase IV. They bind and 
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trap the enzyme-DNA complex [6]. This blocks DNA synthesis and 
cell growth and ultimately shows a lethal effect on the cell [7]. 
Different mechanisms of actions of CF against different organisms 
are shown in table 3. 
  
Table 2: Pharmacokinetic parameters 
Parameter  Values  Reference number 
Half life 3 to 4 h  
3,7,8 Bioavailability (Oral) 69% 
Renal excretion 70 % 
Plasma protein binding 30% 
Volume of distribution 2/3.5 L/kg 
Hepatic metabolism 5% 
 
Table 3: List of target enzymes of different organisms inhibited by ciprofloxacin 
Target enzyme Organism Reference number 
DNA topoisomerase 4 subunit 4 A Haemophilus influenza, Staphylococcus aureus 6,7 
DNA topoisomerase 2-alpha and K+-voltage-gated 
channel subfamily H member 
Human 
DNA gyrase subunit A Haemophilus influenzae, Escherichia coli (strain K12), Bacillus 
subtilis (strain 168), Staphylococcus aureus 
DNA topoisomerase 4 subunit 4 B Bacillus subtilis (strain 168) 
Multidrug resistant protein MdtK Escherichia coli 
 
Dosage forms 
CF is available in the market as tablet, infusion, eye drops, 
suspensions, ointments with varying cost prepared by a number of 
companies to treat various bacterial infections. Table 4 illustrated 
the number of dosage forms of CF available with their cost range and 
number of companies manufacturing these CF dosage forms [10]. 
 
Table 4: Different dosage forms of ciprofloxacin available in the market with cost 
Dosage form Available number  Cost range (Rs)  Number of manufacturing companies Reference number 
Tablets 214 8-125/10 tablets 98  
10 Infusion 17 17.86-/100 ml 14 
Eye drops 28 6-24.80/10 ml 24 
Suspensions 4 27.76-48.50/60 ml 4 
Ointments 4 4.31-10/5 ml 4 
 
Table 5: Different drug delivery systems of ciprofloxacin developed 
Type of drug delivery system Name of formulation Application Reference 
number 
Gastro retentive floating DDS Tablets To achieve the controlled release of the drug 13 
Ophthalmic DDS In-situ gel To achieve sustained drug release 14 
Cutaneous wound closures Hydrogels To treat the wounds infected by pseudomonas aeruginosa. 15 
Controlled release DDS Films To treat periodontitis 16 
Gastro retentive sustained 
release DDS 
Microbeads To Prolong duration of action 17 
Targeted DDS Elastic liposomes To treat acne vulgaris 18 
Sustained release DDS  Floating matrix tablets To extend absorption of CF. 19 
Sustained release DDS Tablets  To prolong the drug release 20 
Controlled DDS  Dental films To treat periodontitis 5 
Ophthalmic DDS Ocular Inserts To treat ocular conjunctivitis 21 
Wound closures Composite films For wound healing  22 
Floating bioadhesive DDS Tablets To increase the stay period of drug in its absorption area and 
to decrease the dosing interval 
23 
 
Swellable and gastro-retentive DDS Tablets To prolong gastric emptying time 24 
Topical DDS Films  To treat periodontitis 25 
Ophthalmic DDS Insitu gel To treat eye infections like dacrocystitis, bacterial 
conjunctivitis corneal ulceration 
26 
 
Multi-unit floating DDS Beads  To know about the effect of additives 27 
Extended-release DDS Tablets To Prolong duration of the release  28 
The novel vesicular carrier 
system 
Niosomal cream To improve skin retention and prolong the local effect on skin 29 
 
Patents filed/Sanctioned 
As per FDA, 12 patents are found in literature for different products or 
activities and also a list of 20 patents are given in the drug bank [11, 12].  
Current research on ciprofloxacin 
Development of drug delivery systems (DDS) 
As CF is a broad spectrum antibiotic it acts on a wide range of 
organisms and prescribed by many doctors, the present review 
work on CF is undertaken. The research work was conducted on this 
drug to improve its applications in different diseased conditions by 
many scientists. Most of the research work was carried out to 
formulate liposomes, films, niosomal creams, gastro-retentive 
tablets, hydrogels, dental films, ocular inserts, and microbeads. It is 
also used to treat acne vulgaris which is a common chronic disease 
of the sebaceous follicles in the form of the liposome drug delivery 
system. The gastro-retentive tablets were formulated to improve 
absorption of the drug as it has a narrow absorption window. 
Likewise, it is used to treat periodontitis, which is effective against 
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periodontal pathogens, in the form of dental films. Ocular inserts 
were developed to treat ophthalmic infections. Hence, the list of research 
work conducted on CF by many researchers is shown in table 5. 
Analytical methods for estimation of ciprofloxacin  
Several analytical methods for the quantitative determination of 
CF in pharmaceutical formulations were developed like 
electrophoresis, UV spectrophotometry, titration, and High-
Performance Liquid Chromatography (HPLC). Quantification is 
necessary to determine the quality of medicine, which are 
available in the market.  
Which are later used for quantification of CF in urine, plasma, animal 
tissue, and other samples. Methods developed for estimation of CF in 
different samples are given in table 6. 
 
Table 6: Analytical methods for estimation of Ciprofloxacin in different samples 
Sample Method Application Reference 
number 
Body fluids HPLC This method is ideal for clinical trials and PK studies of CF 30 
Biological fluids HPLC To study the pharmacokinetics of CF 31 
Plasma and urine HPLC Used to measure only the parent drug in human serum and urine 
but not metabolites 
32 
Pharmaceutical preparations 
and biological fluids 
RP-HPLC Separation of compounds and to determine the pharmacokinetics 
of CF 
33 
Pharmaceutical preparations  HPLC Quantitative determination of 2nd generation quinolones 34 
Ophthalmic solution UV-Visible 
spectrophotometry 
The first derivative method is successfully applied (difficulty with 
excipients can overcome by selecting at appropriate wavelength) 
35 
Pharmaceutical preparations  
 
HPLC with UV detection Highly efficient for quantification in matrices evaluated 9 
Serum and urine HPLC To study the pharmacokinetics of CF in patients receiving 
multiple drug therapy 
36 
 
Interaction and reactions with ciprofloxacin 
Two types of possible interactions were found, those are drug-drug 
and drug-food interaction as shown below 
Drug-drug interaction 
As CF is an inhibitor of CYP 1A2, the drugs majorly metabolized by 
CYP 1A2 metabolized drugs have shown increased plasma 
concentrations when co-administered with CF [37]. Hence, CYP1A2 
metabolized drugs shown adverse reactions when administered 
along with CF [38]. They are around 275 drug interactions listed in 
drug bank [7]. But some drug interactions with CF based on drugs 
category and its effects are shown in table 7. 
Drug-food interaction 
CF, when taken with food, decreased the rate, but not the extent of 
absorption of CF [39]. List of food interactions with CF and its effects 
are shown in table 8. 
 
Table 7: List of drug interactions of ciprofloxacin and its effects 
 Category Effect Reference 
number 
Caffeine and xanthine derivative Reduced clearance of caffeine and a prolongation of its serum half-life  7,37,38 
Class IA or III Antiarrhythmics  CF may have an additive effect on the QT interval  
Histamine H2-receptor Antagonists  No significant effect on the bioavailability of CF.  
Multivalent Cations  Lower serum and urine levels 
Nonsteroidal Anti-Inflammatory Drugs 
(NSAIDs)  
Increase the risk of central nervous system stimulation and convulsive 
seizures.  
Oral Anticoagulants  Increase in oral anticoagulant activity  
 
Table 8: List of interactions with ciprofloxacin dosage forms and its effects 
Dosage form With Effect Reference number 
Tablet Food  Delay in the absorption of CF  
39 Suspension Food  No delay is observed 
Any formulation Dairy products/Calcium-fortified juices Decrease in the absorption of CF 
 
Table 9: Adverse drug reactions of ciprofloxacin 
Organ/System name  ADR Reference 
number 
CNS Nervousness, agitation, insomnia, anxiety, nightmares, dizziness, confusion, tremors, hallucinations, 
psychotic reaction, depression  
38,39,40 
CVS Orthostatic hypotension, Vasculitis 
EYE Blurred vision, burning, stinging, irritation, 
itching, tearing, and redness of eyes, eyelid itching, swelling, or crusting, sensitivity to light 
GI System Nausea, vomiting, diarrhea, constipation, abdominal pain or discomfort, dyspepsia, dysphagia, 
flatulence, pancreatitis, pseudomembranous colitis 
Urinary system Albuminuria, candiduria, renal calculi 
Skin Rashes, exfoliative dermatitis, toxic epidermal necrolysis, erythema, Toxic epidermal necrolysis, 
Stevens-Johnson syndrome 
Hepatic system Jaundice, hepatic necrosis 
Musculoskeletal system Myalgia, myoclonus, tendinitis, tendon rupture 
Others Phototoxicity 
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Adverse drug reactions (ADRs) of CF 
CF use is associated with disabling and potentially irreversible 
serious adverse reactions [38, 39]. CF has also shown some adverse 
effects on different organs or systems of the body as shown below in 
table 9 [40]. 
Miscellaneous research works on ciprofloxacin 
Some different results were found during research on CF and its 
dosage forms by a number of scientists and are discussed below.  
Janis Vella et al., conducted studies on “factors affecting the 
penetration of CF in lower extremity ischemic tissues” indicated the 
decreased tissue concentrations of CF in patients suffering from 
more severe forms of the peripheral arterial disease (PAD) [41]. 
V. V. Sarveshwer Rao et al., conducted studies on “Circadian 
variation in urinary excretion of CF after a single-dose oral 
administration at 1000 and 2200 H in Human subjects” and found a 
significant decrease in the rate and extent of CF excretion during 
their study [42]. Tomasz Kloskowski et al., proposed that this drug 
can serve as an adjuvant treatment for lung cancer, due to its 
capacity of topoisomerase II inhibition [43]. 
Imran Hayder et al., indicated that TiO2-based photocatalysis is a 
feasible way to inactivate the CF drug, as a pretreatment prior to 
further biological treatments [44]. Gayatri Devi Singh et al., indicated 
that, with an increase in duration of UV and sunlight treatment 
duration, the rate of degradation was increased, and led to the 
gradual inactivation of the antibiotic [45]. Abbas Khan et al., 
indicated the change of pharmacokinetics of CF when co-
administered with diclofenac eye drops [46]. Ron E. Polk et al., 
resulted in the possibility of renal failure associated with the 
concomitant administration of cyclosporine and CF [47]. 
A study on “Comparative Activity of CF, Levofloxacin and 
Moxifloxacin against Klebsiella pneumoniae, Pseudomonas 
aeruginosa and Stenotrophomona maltophilia assessed by minimum 
inhibitory concentrations and time-kill Studies indicated the activity 
of CF and levofloxacin antibiotics are equivalent [48]. 
Danni ramdhani et. al conducted studies on “Ciprofloxacin resistance 
among clinical isolates from acute respiratory infections patients at 
community health centers in tasikmalaya, indonesia’’ indicated that 
level of antibiotic (CF) resistance was mediated resistance [49]. 
CONCLUSION 
The present review revealed that analytical methods to determine 
CF was developed for its pharmacokinetic studies in the first decade 
of the selected review period (1985-1995). In the second decade, the 
research work on the development of drug delivery systems of CF 
was found in the literature. Whereas more research papers were 
found in the development of novel drug delivery systems of CF in 
third decade compared to the last 2 decades. The review on CF will 
be useful for further applications and development of improved 
drug delivery systems as it helps in the understanding of available 
applications, drug delivery systems with the already found 
results/reports on increased bioavailability, prolonged release, 
gastric retention etc. 
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